The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

65 participants · First posted Oct 27, 2015

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

132 participants · First posted May 9, 2011

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

208 participants · First posted Oct 12, 2015

TMPRSS2-ERG fusion gene therapy

ERG-344

ERG-245

Eneco Refresh Ltd

Berg LLC

United States

NRG Oncology

United States

Parabilis Medicines Demonstrates First-Ever Degradation of ERG in Prostate Cancer Models

Pro-Neuropeptide Y Emerges as a Circulating Biomarker for Poor Prognosis in Prostate Cancer

BostonGene Presents Six AI-Driven Cancer Research Studies at 2025 ASCO Annual Meeting